|
27 Aug 2026 |
Inventurus Knowledge
|
Consensus Share Price Target
|
1750.60 |
1960.63 |
- |
12.00 |
buy
|
|
|
|
|
06 Aug 2026
|
Inventurus Knowledge
|
Motilal Oswal
|
1750.60
|
2075.00
|
1763.10
(-0.71%)
|
18.53 |
Buy
|
|
|
Inventurus Knowledge Solutions’ (IKS) 1QFY27 USD revenue was up 12% YoY at USD97m (est. USD97m). INR revenue rose 21% YoY to INR8.9b (est. INR8.1b), with EBITDA of INR2.9b (est. INR3.1b) and margin of 33.0%, up 24% YoY (est. 35%), led by strong traction in top accounts.
|
|
08 Jul 2026
|
Inventurus Knowledge
|
Aditya Birla Money Limited
|
1750.60
|
2080.00
|
1831.90
(-4.44%)
|
18.82 |
Buy
|
|
|
IKS's Q1FY27 numbers missed consensus, with revenue up 4.2% QoQ/20.7% YoY and EBITDA margins down 200bps QoQ at 33% (including one-time acquisition costs of Rs 200Mn). However, underlying demand remained healthy, driven by strong client mining and expansion across key accounts and growing traction in large health systems. We believe the recent TruBridge acquisition significantly expands IKS' presence in the rural and community healthcare market and strengthens its platform play. While IKS revised TruBridge's revenue run-rate to USD 300mn (vs. USD 340mn earlier), EBITDA remains...
|
|
15 May 2026
|
Inventurus Knowledge
|
Aditya Birla Money Limited
|
1750.60
|
1960.00
|
1595.30
(9.73%)
|
11.96 |
Buy
|
|
|
Healthy outlook; platform model a key moat IKS's positioning as a platform-based system of action with embedded AI capabilities continues to differentiate it from point solution peers. Management remains confident of outpacing industry growth (outsourcing provider TAM expected to grow at ~12% CAGR), on the back of a healthy deal pipeline, cross-sell opportunities, platform-led expansion and scaling of outcome-oriented deals. Post the TruBridge acquisition, management has outlined a medium-term target of growing its EBITDA by nearly ~3x to...
|
|
26 Apr 2026
|
Inventurus Knowledge
|
Motilal Oswal
|
1750.60
|
1902.00
|
1438.00
(21.74%)
|
Target met |
Buy
|
|
|
IKS announced the acquisition of TruBridge, a leading healthcare IT and RCM services provider in the US, with revenue of USD347m in CY25, almost equal to IKS’s revenue base.
|
|
05 Feb 2026
|
Inventurus Knowledge
|
Motilal Oswal
|
1750.60
|
2109.00
|
1703.70
(2.75%)
|
20.47 |
Buy
|
|
|
IKS’s 3QFY26 USD revenue rose 19% YoY to USD93m, led by strong performance from top clients and healthy contribution from new deals and partnerships.
|
|
12 Nov 2025
|
Inventurus Knowledge
|
ICICI Securities Limited
|
1750.60
|
2000.00
|
1644.70
(6.44%)
|
14.25 |
Buy
|
|
|
We met IKS’ management at I-Sec conference. IKS is focusing on continuing the traction on full-platform deals, increasing cross-selling with AQuity clients, using AI to gain operating margin leverage and increase non-linearity between revenue and headcount growth and working with hospitals.
|
|
10 Mar 2025
|
Inventurus Knowledge
|
ICICI Securities Limited
|
1750.60
|
1820.00
|
1732.15
(1.07%)
|
Target met |
Hold
|
|
|
IKS Health (IKS) is a Platform as a Service (PaaS) company that caters to US’ healthcare provider segment. It focusses on outsourcing the routine chores of physicians. IKS’ platform has 16 key features, spanning across chores in a physician’s value chain, bundled into admin offerings and clinical offerings.
|
|
12 Dec 2024
|
Inventurus Knowledge
|
Ashika Research
|
1750.60
|
|
|
|
IPO Note
|
|
|
|
|
11 Dec 2024
|
Inventurus Knowledge
|
SBI Securities
|
1750.60
|
|
|
|
IPO Subscribe
|
|
|
|
|
10 Dec 2024
|
Inventurus Knowledge
|
Ventura
|
1750.60
|
|
|
|
IPO Subscribe
|
|
|
|